Will Combination Therapies With Immunotherapy Become the New Standard of Care For NSCLC? – Targeted Oncology
Targeted Oncology |
Will Combination Therapies With Immunotherapy Become the New Standard of Care For NSCLC?
Targeted Oncology After the accelerated FDA approval of pembrolizumab (Keytruda) for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell lung cancer (NSCLC), rapid growth … |
